Correction: 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial.
[This corrects the article DOI: 10.1371/journal.pone.0251716.].
Main Author: | PLOS ONE Staff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0253252 |
Similar Items
-
Retraction: 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial.
by: PLOS ONE Editors
Published: (2024-01-01) -
2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial.
by: Msolli Mohamed Amine, et al.
Published: (2021-01-01) -
Retraction: 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial
Published: (2024-01-01) -
Expression of concern: ‘Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial’
Published: (2023-08-01) -
Two-day seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial
by: Salma Messous, et al.
Published: (2022-06-01)